TOP STORY RNA Offers a Safer Way to Reprogram Cells Researchers have shown, for the first time, that they can deliver reprogramming genes using RNA. This method could prove much safer than DNA-based reprogramming. [Press release from Massachusetts Institute of Technology discussing online prepublication in PLoS One]
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome Researchers generated patient-specific pluripotent stem cells from members of a family affected by long-QT syndrome type 1 and induced them to differentiate into functional cardiac myocytes. The patient-derived cells recapitulated the electrophysiological features of the disorder. [N Engl J Med] Promotion of Direct Reprogramming by Transformation-Deficient Myc Researchers report that the promotion of induced pluripotent stem cell generation by Myc is independent of its transformation property. [Proc Natl Acad Sci U S A] Generation of Genetically Modified Rats from Embryonic Stem Cells To monitor the pluripotency of rat embryonic stem cells, researchers generated Oct4-Venus transgenic rats via a conventional method, in which Venus is expressed by the Oct4 promoter/enhancer. [Proc Natl Acad Sci U S A] Deletion of TDP-43 Down-Regulates Tbc1d1, a Gene Linked to Obesity, and Alters Body Fat Metabolism Results establish that Tat activating regulatory DNA-binding protein (TDP-43) is critical for fat metabolism and embryonic stem cell survival. [Proc Natl Acad Sci U S A] Synthesized Basement Membranes Direct the Differentiation of Mouse Embryonic Stem Cells into Pancreatic Lineages On a synthesized basement membrane, mouse embryonic stem or induced pluripotent stem cells sequentially differentiated into the definitive endoderm, pancreatic progenitor cells, and then insulin-expressing pancreatic beta cells in vitro. [J Cell Sci] Cell Line-Dependent Differentiation of Induced Pluripotent Stem Cells into Cardiomyocytes in Mice Mouse induced pluripotent stem (iPS) cells differentiate into cardiomyocytes in a cell line-dependent manner. Trichostatin A induces myocardial differentiation in mouse iPS cells and might be useful to overcome cell line variation in the differentiation efficiency. [Cardiovasc Res] The Efficient Generation of Induced Pluripotent Stem (iPS) Cells From Adult Mouse Adipose Tissue-Derived and Neural Stem Cells Findings confirm that adipose tissue-derived cells are an ideal candidate as a readily accessible somatic cell type for high efficiency establishment of iPS cell lines. [Cell Transplant] Involvement of Caveolin-1 in Fibronectin-Induced Mouse Embryonic Stem Cell Proliferation: Role of FAK, RhoA, PI3K/Akt, and ERK 1/2 Pathways Researchers conclude that fibronectin stimulates mouse embryonic stem cell proliferation via RhoA-PI3K/Akt-ERK 1/2 pathway through caveolin-1 phosphorylation. [J Cell Physiol] Application of Induced Pluripotent Stem (iPS) Cells in Periodontal Tissue Regeneration iPS cells combined with enamel matrix derivative provide a valuable tool for periodontal tissue engineering, by promoting the formation of new cementum, alveolar bone, and normal periodontal ligament. [J Cell Physiol] Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins Researchers show that combined knockdown of interferon-beta (Ifnb1), Eif2ak2, and Stat2 rescues cells from the innate immune response triggered by frequent long-RNA transfection. Using this technique, they were able to transfect primary human fibroblasts every 24 hours with RNA encoding the reprogramming proteins Oct4, Sox2, Klf4, and Utf1. [PLoS One]
|
POLICY NEWS NIH Takes on New Role in Fight Against Rare Diseases A government program focusing on rare diseases, the Therapeutics for Rare and Neglected Diseases (TRND) program, has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs. TRND will work together with scientists, advocates and others to do the required research and testing on drugs before a compound can be tried in humans in a clinical trial. [National Institutes of Health, United States] NIH Asks for Input on Closing Loophole in Conflict-of-Interest Rule Responding to yet another flap about the influence of drug companies on biomedical research, the National Institutes of Health (NIH) has decided it needs more time to revise its rules for policing conflicts of interest so that sanctions will move with an investigator if he or she changes institutions. [National Institutes of Health, United States] Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors [Docket Number NIH-2010-0001] [Department of Health and Human Services, United States] National Institute of General Medical Sciences; Notice of Closed Meeting (Doc. 2010-18088) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meeting (Doc. 2010-18052) [National Institutes of Health, United States] Instrument Development for Biomedical Applications (R21) (RFA-RR-10-009) [National Institutes of Health, United States] Bioengineering Research Partnerships (BRP)[R01] (PAR-10-234) [National Institutes of Health, United States] National Institute of Biomedical Imaging and Bioengineering Program Project (P01) Applications (PAR-10-233) [National Institutes of Health, United States]
|
EVENTS Cold Spring Harbor Workshop on Stem Cells July 30-August 5, 2010 Cold Spring Harbor, United States 2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2) August 2-4, 2010 Singapore 9th Mount Desert Island Stem Cell Symposium August 6-7, 2010 Salsbury Cove, United States Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences 2nd Annual World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Hydra VI: The European Summer School on Stem Cells & Regenerative Medicine September 11-17, 2010 Hydra, Greece Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010 September 15-17, 2010 Sydney, Australia 5th Annual Meeting of the German Society for Stem Cell Research September 30-October 2, 2010 Lübeck, Germany 5th World Congress on Preventive & Regenerative Medicine (WCRM) 2010 October 5-7, 2010 Hannover, Germany Induced Pluripotent Stem Cells: Production and Utility in Regenerative Medicine October 7, 2010 Hertfordshire, United KingdomFraunhofer Life Science Symposium Leipzig 2010 October 29-30, 2010 Leipzig, Germany Select Biosciences 2nd International Forum on Stem Cells November 12-13, 2010 Tianjin, China Stem Cell Network 10th Annual Scientific Meeting November 22-24, 2010 Calgary, Canada Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference December 5-8, 2010 Orlando, United States NEW Biotech Showcase 2011 January 10-12, 2011 San Francisco, USA Stem Cells World Congress January 24-25, 2011 San Diego, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with ESC & iPSC News. Visit here to post your career opportunities.
|
|